What is Teewinot Life Sciences?
Teewinot Life Sciences is a global biopharmaceutical company dedicated to the ethical development of cannabinoid-based drugs and the biocatalytic production of pharmaceutical-grade cannabinoids. Through its subsidiary, Full Spectrum Laboratories, Ltd., Teewinot has pioneered patented processes utilizing biocatalysis and synthetic biology to create pure cannabinoids. Headquartered in Tampa, Florida, the company not only manufactures these compounds but also licenses its proprietary technology, aiming to deliver cost-effective and highly pure cannabinoids to the market. This focus positions Teewinot at the intersection of biotechnology, pharmaceutical innovation, and the burgeoning cannabinoid industry.
How much funding has Teewinot Life Sciences raised?
Teewinot Life Sciences has raised a total of $19.3M across 2 funding rounds:
Series A
$7M
Series B
$12.3M
Series A (2016): $7M with participation from Tuatara Capital
Series B (2017): $12.3M led by Tuatara Capital
Key Investors in Teewinot Life Sciences
Tuatara Capital
Tuatara Capital is a venture capital firm dedicated to supporting innovative entrepreneurs and building successful companies. They focus on forming foundational partnerships, providing guidance and resources throughout the business lifecycle, and collaborating with diverse professionals and trailblazing innovators to create leading growth-stage companies.
What's next for Teewinot Life Sciences?
The substantial enterprise-level funding, highlighted by the recent strategic investment, signals a pivotal phase for Teewinot Life Sciences. This capital infusion is expected to accelerate the company's research and development initiatives, potentially expanding its pipeline of cannabinoid-based therapeutics and enhancing its biocatalytic production capabilities. Further investment will likely support scaling operations, navigating regulatory pathways for drug approval, and broadening market penetration. Teewinot's commitment to proprietary technology and pharmaceutical-grade production suggests a strategic focus on establishing a strong competitive advantage in the rapidly evolving biopharmaceutical landscape.
See full Teewinot Life Sciences company page
